INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360294, 'Avapritinib', 'Monomethyl fumarate', 'Moderate', 'The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', 'DDInter', 1767317475, 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.', 'Synergism', 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360295, 'Avapritinib', 'Mumps virus strain B level jeryl lynn live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317475, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360296, 'Avapritinib', 'Nabumetone', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360297, 'Avapritinib', 'Nafcillin', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360298, 'Avapritinib', 'Naproxen', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360299, 'Avapritinib', 'Natalizumab', 'Major', 'Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.', 'DDInter', 1767317475, 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.', 'Synergism', 'The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360300, 'Avapritinib', 'Nefazodone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360301, 'Avapritinib', 'Nelfinavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360302, 'Avapritinib', 'Nepafenac (ophthalmic)', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', 'DDInter', 1767317475, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360303, 'Avapritinib', 'Nevirapine', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360304, 'Avapritinib', 'Nilotinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360305, 'Avapritinib', 'Niraparib', 'Moderate', 'Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.', 'DDInter', 1767317475, 'Caution is advised if niraparib is prescribed with other myelosuppressive agents.', 'Synergism', 'Caution is advised if niraparib is prescribed with other myelosuppressive agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360306, 'Avapritinib', 'Ocrelizumab', 'Moderate', 'The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.', 'DDInter', 1767317475, 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.', 'Synergism', 'The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360307, 'Avapritinib', 'Octreotide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360308, 'Avapritinib', 'Olaparib', 'Moderate', 'Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.', 'DDInter', 1767317475, 'Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.', 'Synergism', 'Caution is advised if olaparib is prescribed with other myelosuppressive agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360309, 'Avapritinib', 'Omacetaxine mepesuccinate', 'Major', 'Coadministration of omacetaxine and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with omacetaxine is associated with a high frequency of thrombocytopenia.', 'DDInter', 1767317475, 'Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient''s platelet count is less than 50,000 per microliter. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The CBC and platelet count should be monitored according to the manufacturer''s recommendations.', 'Synergism', 'Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient''s platelet count is less than 50,000 per microliter.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360310, 'Avapritinib', 'Oritavancin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360311, 'Avapritinib', 'Osilodrostat', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360312, 'Avapritinib', 'Oxaprozin', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360313, 'Avapritinib', 'Oxcarbazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360314, 'Avapritinib', 'Ozanimod', 'Major', 'Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'DDInter', 1767317475, 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360315, 'Avapritinib', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360316, 'Avapritinib', 'Panobinostat', 'Major', 'Coadministration of panobinostat and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with panobinostat has been associated with severe thrombocytopenia and hemorrhage (including gastrointestinal and pulmonary hemorrhage) with fatal outcomes. The risk may be increased in patients with coagulation disorders or those on chronic anticoagulation therapy.', 'DDInter', 1767317475, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood cell count should be performed prior to and at least weekly during treatment according to treatment protocols, including monitoring for thrombocytopenia. Dose modifications may be required based on individual patient tolerability. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360317, 'Avapritinib', 'Paroxetine', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', 'DDInter', 1767317475, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360318, 'Avapritinib', 'Pasireotide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360319, 'Avapritinib', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360320, 'Avapritinib', 'Pegfilgrastim', 'Moderate', 'INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.', 'DDInter', 1767317475, 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.', 'Antagonism', 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360321, 'Avapritinib', 'Pentobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360322, 'Pentosan polysulfate', 'Avapritinib', 'Moderate', 'Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', 'DDInter', 1767317475, 'Caution is advised if pentosan polysulfate sodium is used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if pentosan polysulfate sodium is used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360323, 'Pexidartinib', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360324, 'Phenobarbital', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360325, 'Phenylbutazone', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360326, 'Phenytoin', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360327, 'Piroxicam', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360328, 'Pitolisant', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360329, 'Plicamycin', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360330, 'Poliovirus type 1 antigen (formaldehyde inactivated)', 'Avapritinib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360331, 'Ponatinib', 'Avapritinib', 'Major', 'Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with ponatinib is associated with severe, sometimes fatal hemorrhage including cerebral and gastrointestinal hemorrhage.', 'DDInter', 1767317475, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ponatinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ponatinib.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360332, 'Porfimer sodium', 'Avapritinib', 'Moderate', 'Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.', 'DDInter', 1767317475, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', 'Synergism', 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360333, 'Posaconazole', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360334, 'Prasugrel', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360335, 'Primidone', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360336, 'Radium Ra 223 dichloride', 'Avapritinib', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 1767317475, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360337, 'Ramucirumab', 'Avapritinib', 'Major', 'Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab can cause bleeding, including severe and sometimes fatal hemorrhagic complications.', 'DDInter', 1767317475, 'Concomitant use of ramucirumab and medications that interfere with platelet function or coagulation should be approached cautiously. Close clinical and laboratory observation for bleeding complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Ramucirumab should be permanently discontinued in patients who experience severe bleeding.', 'Synergism', 'Concomitant use of ramucirumab and medications that interfere with platelet function or coagulation should be approached cautiously.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360338, 'Ranolazine', 'Avapritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360339, 'Regorafenib', 'Avapritinib', 'Major', 'Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with regorafenib is associated with a high frequency of hemorrhage and thrombocytopenia. Coadministration of regorafenib with strong UGT1A9 inhibitors such as mefenamic acid or diflunisal may theoretically increase systemic exposure to regorafenib.', 'DDInter', 1767317475, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with regorafenib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin.', 'Synergism', 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with regorafenib.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360340, 'Reteplase', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360341, 'Ribociclib', 'Avapritinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the starting dosage of avapritinib from 300 mg orally once daily to 100 mg orally once daily.', 'Metabolism', 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360342, 'Rifabutin', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360343, 'Rifampicin', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360344, 'Rifapentine', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360345, 'Rilonacept', 'Avapritinib', 'Moderate', 'The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.', 'Synergism', 'The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360346, 'Ritonavir', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360347, 'Rivaroxaban', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360348, 'Roflumilast', 'Avapritinib', 'Moderate', 'The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.', 'DDInter', 1767317475, 'According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).', 'Synergism', 'According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360349, 'Rotavirus vaccine', 'Avapritinib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317475, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360350, 'Rubella virus vaccine', 'Avapritinib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317475, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360351, 'Rucaparib', 'Avapritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360352, 'Rufinamide', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360353, 'Ruxolitinib', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360354, 'Samarium (153Sm) lexidronam', 'Avapritinib', 'Major', 'Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.', 'DDInter', 1767317475, 'The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.', 'Synergism', 'The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360355, 'Saquinavir', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360356, 'Sargramostim', 'Avapritinib', 'Moderate', 'INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.', 'DDInter', 1767317475, 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.', 'Antagonism', 'Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360357, 'Pfizer-BioNTech Covid-19 Vaccine', 'Avapritinib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360358, 'Secobarbital', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360359, 'Selpercatinib', 'Avapritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360360, 'Sertraline', 'Avapritinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', 'DDInter', 1767317475, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360361, 'Sibutramine', 'Avapritinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', 'DDInter', 1767317475, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360362, 'Siponimod', 'Avapritinib', 'Major', 'Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.', 'DDInter', 1767317475, 'The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.', 'Synergism', 'The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360363, 'Sipuleucel-T', 'Avapritinib', 'Moderate', 'Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.', 'DDInter', 1767317475, 'Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.', 'Others', 'Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360364, 'Smallpox (Vaccinia) Vaccine, Live', 'Avapritinib', 'Major', 'The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).', 'Others', 'Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360365, 'Sodium phosphate, monobasic (p32)', 'Avapritinib', 'Moderate', 'The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.', 'DDInter', 1767317475, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360366, 'Somapacitan', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360367, 'Somatrem', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360368, 'Somatotropin', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360369, 'St. John''s Wort', 'Avapritinib', 'Major', 'Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent or moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360370, 'Streptokinase', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360371, 'Strontium chloride Sr-89', 'Avapritinib', 'Moderate', 'The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.', 'DDInter', 1767317475, 'Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360372, 'Sulfinpyrazone', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360373, 'Sulindac', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360374, 'Sunitinib', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360375, 'Suprofen (ophthalmic)', 'Avapritinib', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', 'DDInter', 1767317475, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360376, 'Suvorexant', 'Avapritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360377, 'Talimogene laherparepvec', 'Avapritinib', 'Major', 'Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient''s immune system has sufficiently recovered.', 'Synergism', 'Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360378, 'Tazemetostat', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360379, 'Telaprevir', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360380, 'Telithromycin', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360381, 'Telotristat ethyl', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360382, 'Tenecteplase', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360383, 'Teriflunomide', 'Avapritinib', 'Major', 'The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide''s active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.', 'DDInter', 1767317475, 'Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years.', 'Synergism', 'Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360384, 'Ticagrelor', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360385, 'Ticlopidine', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360386, 'Tinzaparin', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360387, 'Tipranavir', 'Avapritinib', 'Major', 'Theoretically, tipranavir may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, high supplemental dosages of vitamin E, or agents that commonly cause thrombocytopenia.', 'DDInter', 1767317475, 'Caution is advised if tipranavir/ritonavir is used in combination with other drugs that affect hemostasis. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if tipranavir/ritonavir is used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360388, 'Tirofiban', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360389, 'Tofacitinib', 'Avapritinib', 'Major', 'Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.', 'DDInter', 1767317475, 'Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.', 'Others', 'Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360390, 'Tolmetin', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360391, 'Topotecan', 'Avapritinib', 'Moderate', 'The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.', 'DDInter', 1767317475, 'Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Caution is advised if topotecan is used with other cytotoxic agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360392, 'Tositumomab', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360393, 'Treprostinil', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360394, 'Trichophyton mentagrophytes', 'Avapritinib', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360395, 'Troglitazone', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360396, 'Troleandomycin', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360397, 'Tuberculin purified protein derivative', 'Avapritinib', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360398, 'Tucatinib', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360399, 'Typhoid vaccine (inactivated)', 'Avapritinib', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360400, 'Typhoid vaccine (live)', 'Avapritinib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317475, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360401, 'Upadacitinib', 'Avapritinib', 'Major', 'Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.', 'DDInter', 1767317475, 'Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.', 'Others', 'Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360402, 'Urokinase', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360403, 'Ustekinumab', 'Avapritinib', 'Moderate', 'The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', 'DDInter', 1767317475, 'Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.', 'Others', 'Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360404, 'Valganciclovir', 'Avapritinib', 'Moderate', 'The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.', 'DDInter', 1767317475, 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.', 'Synergism', 'Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360405, 'Varicella Zoster Vaccine (Recombinant)', 'Avapritinib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317475, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360406, 'Vemurafenib', 'Avapritinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of avapritinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360407, 'Venlafaxine', 'Avapritinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', 'DDInter', 1767317475, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360408, 'Verapamil', 'Avapritinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the starting dosage of avapritinib from 300 mg orally once daily to 100 mg orally once daily.', 'Metabolism', 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360409, 'Verteporfin', 'Avapritinib', 'Moderate', 'Concomitant use of verteporfin with other known photosensitizing agents may increase the risk of photosensitivity reactions. Medicinal products with known phototoxic or photoallergic potential include fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, and hypericin extracts (e.g., St John''s Wort).', 'DDInter', 1767317475, 'Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid exposure of skin or eyes to sunlight or bright indoor lights (e.g., examination lamps, operating room lamps, tanning beds, lights at close proximity) for 5 days after administration of verteporfin.', 'Synergism', 'Caution is advised and pharmacologic response to photodynamic therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360410, 'Vilazodone', 'Avapritinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', 'DDInter', 1767317475, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360411, 'Vorapaxar', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360412, 'Voriconazole', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360413, 'Vortioxetine', 'Avapritinib', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', 'DDInter', 1767317475, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360414, 'Voxelotor', 'Avapritinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the starting dosage of avapritinib from 300 mg orally once daily to 100 mg orally once daily.', 'Metabolism', 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360415, 'Warfarin', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360416, 'Yellow Fever Vaccine', 'Avapritinib', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317475, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360417, 'Zafirlukast', 'Avapritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 1767317475, 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360418, 'Zanubrutinib', 'Avapritinib', 'Major', 'Coadministration of zanubrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', 'DDInter', 1767317475, 'Concomitant use of zanubrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Discontinue zanubrutinib if intracranial hemorrhage of any grade occurs.', 'Synergism', 'Concomitant use of zanubrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360419, 'Bexarotene (topical)', 'Octasulfur (topical)', 'Moderate', 'Concomitant use of retinoids and keratolytic or astringent topicals may result in excessive irritation and/or drying.', 'DDInter', 1767317475, 'Depending on circumstances (e.g., areas of application), concomitant use should preferably be avoided, and a rest period considered in between use of these products.', 'Others', 'Depending on circumstances (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360420, 'Tazarotene (topical)', 'Octasulfur (topical)', 'Moderate', 'Concomitant use of retinoids and keratolytic or astringent topicals may result in excessive irritation and/or drying.', 'DDInter', 1767317475, 'Depending on circumstances (e.g., areas of application), concomitant use should preferably be avoided, and a rest period considered in between use of these products.', 'Others', 'Depending on circumstances (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360421, 'Trifarotene (topical)', 'Octasulfur (topical)', 'Moderate', 'Concomitant use of retinoids and keratolytic or astringent topicals may result in excessive irritation and/or drying.', 'DDInter', 1767317475, 'Depending on circumstances (e.g., areas of application), concomitant use should preferably be avoided, and a rest period considered in between use of these products.', 'Others', 'Depending on circumstances (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360422, 'Amprenavir', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360423, 'Boceprevir', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360424, 'Carbamazepine', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer. In patients already receiving avatrombopag therapy and starting a moderate or strong dual CYP450 2C9 and 3A4 inducer, platelet counts should be monitored and avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360425, 'Carfilzomib', 'Avatrombopag', 'Major', 'Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent use of other agents also associated with this adverse effect can potentiate the risk.', 'DDInter', 1767317475, 'Caution is advised when carfilzomib is used with other drugs that can increase the risk of thrombosis. Thromboprophylaxis should be considered according to local treatment protocols. Close monitoring for thromboembolic events is recommended in patients with known risk factors (e.g., prior thrombosis, hyperlipidemia, hypertension, smoking) for thromboembolism. Patients should be advised to seek immediate medical attention if they develop symptoms of thromboembolism, such as shortness of breath, chest pain, hemoptysis, or arm or leg swelling or pain.', 'Synergism', 'Caution is advised when carfilzomib is used with other drugs that can increase the risk of thrombosis.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360426, 'Ceritinib', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360427, 'Clarithromycin', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360428, 'Cobicistat', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360429, 'Dabrafenib', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer. In patients already receiving avatrombopag therapy and starting a moderate or strong dual CYP450 2C9 and 3A4 inducer, platelet counts should be monitored and avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360430, 'Delavirdine', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360431, 'Enzalutamide', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer. In patients already receiving avatrombopag therapy and starting a moderate or strong dual CYP450 2C9 and 3A4 inducer, platelet counts should be monitored and avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360432, 'Fluconazole', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inhibitors of CYP450 2C9 and 3A4 may increase the systemic exposure (AUC) to avatrombopag. This may lead to an increased risk of avatrombopag toxicities including thromboembolic events such as portal vein thrombosis and septic thrombophlebitis. Metabolic clearance via CYP450 2C9 appears be more significant than CYP450 3A4. In addition, pooled pharmacogenomic analysis of avatrombopag studies suggests that CYP450 2C9 polymorphisms may also impact the clearance of avatrombopag.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends a reduced starting dose of avatrombopag 20 mg orally three times a week when used concomitantly with a moderate to potent dual inhibitor of CYP450 2C9 and 3A4. In patients already receiving avatrombopag therapy, monitoring of platelet counts is recommended when a moderate to potent dual CYP450 2C9 and 3A4 inhibitor is added, and the avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dosage adjustments are not available for poor metabolizers of CYP450 2C9. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends a reduced starting dose of avatrombopag 20 mg orally three times a week when used concomitantly with a moderate to potent dual inhibitor of CYP450 2C9 and 3A4.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360433, 'Idelalisib', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360434, 'Imatinib', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inhibitors of CYP450 2C9 and 3A4 may increase the systemic exposure (AUC) to avatrombopag. This may lead to an increased risk of avatrombopag toxicities including thromboembolic events such as portal vein thrombosis and septic thrombophlebitis. Metabolic clearance via CYP450 2C9 appears be more significant than CYP450 3A4. In addition, pooled pharmacogenomic analysis of avatrombopag studies suggests that CYP450 2C9 polymorphisms may also impact the clearance of avatrombopag.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends a reduced starting dose of avatrombopag 20 mg orally three times a week when used concomitantly with a moderate to potent dual inhibitor of CYP450 2C9 and 3A4. In patients already receiving avatrombopag therapy, monitoring of platelet counts is recommended when a moderate to potent dual CYP450 2C9 and 3A4 inhibitor is added, and the avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dosage adjustments are not available for poor metabolizers of CYP450 2C9. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends a reduced starting dose of avatrombopag 20 mg orally three times a week when used concomitantly with a moderate to potent dual inhibitor of CYP450 2C9 and 3A4.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360435, 'Indinavir', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360436, 'Interferon alfa-n1', 'Avatrombopag', 'Moderate', 'Interferon preparations have been known to reduce platelet counts. This should be considered when avatrombopag is used concomitantly with interferon preparations as therapeutic efficacy may be diminished.', 'DDInter', 1767317475, 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', 'Antagonism', 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360437, 'Interferon alfa-n3', 'Avatrombopag', 'Moderate', 'Interferon preparations have been known to reduce platelet counts. This should be considered when avatrombopag is used concomitantly with interferon preparations as therapeutic efficacy may be diminished.', 'DDInter', 1767317475, 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', 'Antagonism', 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360438, 'Interferon alfacon-1', 'Avatrombopag', 'Moderate', 'Interferon preparations have been known to reduce platelet counts. This should be considered when avatrombopag is used concomitantly with interferon preparations as therapeutic efficacy may be diminished.', 'DDInter', 1767317475, 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', 'Antagonism', 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360439, 'Interferon beta-1a', 'Avatrombopag', 'Moderate', 'Interferon preparations have been known to reduce platelet counts. This should be considered when avatrombopag is used concomitantly with interferon preparations as therapeutic efficacy may be diminished.', 'DDInter', 1767317475, 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', 'Antagonism', 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360440, 'Interferon beta-1b', 'Avatrombopag', 'Moderate', 'Interferon preparations have been known to reduce platelet counts. This should be considered when avatrombopag is used concomitantly with interferon preparations as therapeutic efficacy may be diminished.', 'DDInter', 1767317475, 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', 'Antagonism', 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360441, 'Interferon gamma-1b', 'Avatrombopag', 'Moderate', 'Interferon preparations have been known to reduce platelet counts. This should be considered when avatrombopag is used concomitantly with interferon preparations as therapeutic efficacy may be diminished.', 'DDInter', 1767317475, 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', 'Antagonism', 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360442, 'Itraconazole', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360443, 'Avatrombopag', 'Ketoconazole', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360444, 'Avatrombopag', 'Lonafarnib', 'Moderate', 'Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.', 'DDInter', 1767317475, 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects. The prescribing information recommends avoiding concomitant use of lonafarnib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges when possible. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360445, 'Avatrombopag', 'Mitotane', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360446, 'Avatrombopag', 'Nefazodone', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360447, 'Avatrombopag', 'Nelfinavir', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360448, 'Avatrombopag', 'Nitisinone', 'Moderate', 'Coadministration with nitisinone may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C9, such as warfarin and phenytoin. The proposed mechanism is decreased clearance due to nitisinone-mediated inhibition of CYP450 2C9 isoenzyme.', 'DDInter', 1767317475, 'If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.g., celecoxib, tolbutamide) or CYP450 2C9 substrates with a narrow therapeutic index (e.g., phenytoin, warfarin), the dosage of the drug metabolized by CYP450 2C9 should be reduced by one-half and additional dosage adjustments made as needed to maintain therapeutic drug concentrations. Clinical and laboratory monitoring should be considered whenever nitisinone is added to or withdrawn from therapy with CYP450 2C9 substrates. Refer to individual substrate prescribing information for additional dosing recommendations.', 'Metabolism', 'If nitisinone is used concomitantly with sensitive CYP450 2C9 substrates (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360449, 'Avatrombopag', 'Peginterferon beta-1a', 'Moderate', 'Interferon preparations have been known to reduce platelet counts. This should be considered when avatrombopag is used concomitantly with interferon preparations as therapeutic efficacy may be diminished.', 'DDInter', 1767317475, 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', 'Antagonism', 'Patients should be monitored for decreased response to avatrombopag during concomitant treatment with interferon preparations.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360450, 'Pexidartinib', 'Avatrombopag', 'Moderate', 'Coadministration with pexidartinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is increased clearance due to pexidartinib-mediated induction of CYP450 3A4 isoenzyme.', 'DDInter', 1767317475, 'Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when pexidartinib is prescribed in combination with drugs that are substrates of CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring of the CYP450 3A4 substrate drug should be considered whenever pexidartinib is added to or withdrawn from therapy with these drugs.', 'Metabolism', 'Concomitant administration of pexidartinib with drugs that are substrates of CYP450 3A4 should generally be avoided, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360451, 'Phenobarbital', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360452, 'Phenytoin', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer. In patients already receiving avatrombopag therapy and starting a moderate or strong dual CYP450 2C9 and 3A4 inducer, platelet counts should be monitored and avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360453, 'Posaconazole', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360454, 'Primidone', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360455, 'Rifabutin', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360456, 'Rifampicin', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer. In patients already receiving avatrombopag therapy and starting a moderate or strong dual CYP450 2C9 and 3A4 inducer, platelet counts should be monitored and avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360457, 'Rifapentine', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer. In patients already receiving avatrombopag therapy and starting a moderate or strong dual CYP450 2C9 and 3A4 inducer, platelet counts should be monitored and avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360458, 'Ritonavir', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360459, 'Saquinavir', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360460, 'St. John''s Wort', 'Avatrombopag', 'Major', 'Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may lead to reduced efficacy.', 'DDInter', 1767317475, 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer. In patients already receiving avatrombopag therapy and starting a moderate or strong dual CYP450 2C9 and 3A4 inducer, platelet counts should be monitored and avatrombopag dose adjusted according to the manufacturer''s product labeling as necessary. Dose adjustments are not recommended when prescribed for the treatment of thrombocytopenia in adult patients with chronic liver disease undergoing a procedure.', 'Metabolism', 'For the treatment of patients with chronic immune thrombocytopenia, the manufacturer recommends an increased starting dose of avatrombopag 40 mg orally once daily when used concomitantly with a moderate to potent dual CYP450 2C9 and 3A4 inducer.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360461, 'Telaprevir', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360462, 'Telithromycin', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360463, 'Tucatinib', 'Avatrombopag', 'Moderate', 'Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates. The mechanism involves tucatinib-mediated inhibition of CYP450 3A isoenzymes.', 'DDInter', 1767317475, 'Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever tucatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360464, 'Voriconazole', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', 'DDInter', 1767317475, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360465, 'Avelumab', 'Lenalidomide', 'Major', 'Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase the risk of mortality in patients with multiple myeloma. The mechanism has not been established.', 'DDInter', 1767317475, 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', 'Others', 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360466, 'Pomalidomide', 'Avelumab', 'Major', 'Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase the risk of mortality in patients with multiple myeloma. The mechanism has not been established.', 'DDInter', 1767317475, 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', 'Others', 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360467, 'Thalidomide', 'Avelumab', 'Major', 'Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase the risk of mortality in patients with multiple myeloma. The mechanism has not been established.', 'DDInter', 1767317475, 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', 'Others', 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360468, 'Aluminum hydroxide', 'Axitinib', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360469, 'Aminoglutethimide', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360470, 'Amprenavir', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360471, 'Axitinib', 'Artesunate', 'Moderate', 'Coadministration with potent inhibitors of uridine diphosphate glucuronosyltransferase (UGT) may increase the peak plasma concentration (Cmax) and systemic exposure (AUC) of dihydroartemisinin (DHA), an active metabolite of artesunate and substrate of UGT 1A9 or 2B7. Increased exposure to artesunate may increase the risk of adverse effects such as anemia, increased liver transaminases, thrombocytopenia, hyperbilirubinemia, acute renal failure, and leukocytosis.', 'DDInter', 1767317475, 'Monitoring for adverse reactions is recommended if artesunate is coadministered with potent UGT inhibitors. Dosage adjustments or alternative treatments may be required based on clinical response and tolerance.', 'Others', 'Monitoring for adverse reactions is recommended if artesunate is coadministered with potent UGT inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360472, 'Bedaquiline', 'Axitinib', 'Moderate', 'Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 1767317475, 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.', 'Synergism', 'The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360473, 'Berotralstat', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360474, 'Bexarotene', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360475, 'Bicalutamide', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360476, 'Boceprevir', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360477, 'Bosentan', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360478, 'Brentuximab vedotin', 'Axitinib', 'Moderate', 'Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 1767317475, 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Synergism', 'The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360479, 'Butabarbital', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360480, 'Butalbital', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360481, 'Calaspargase pegol', 'Axitinib', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 1767317475, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360482, 'Calcium carbonate', 'Axitinib', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360483, 'Cannabidiol', 'Axitinib', 'Moderate', 'Coadministration of cannabidiol with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cannabidiol causes dose-related elevations of liver transaminases, both alanine aminotransferase (ALT) and aspartate aminotransferase (AST).', 'DDInter', 1767317475, 'Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa. Serum transaminases and total bilirubin levels should be obtained prior to initiating cannabidiol, and patients with elevated baseline transaminase levels above 3 times the ULN accompanied by elevations in bilirubin above 2 times the ULN should be evaluated. Patients who develop clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, jaundice, dark urine) should have serum transaminases and total bilirubin measured promptly, and cannabidiol treatment interrupted or discontinued as appropriate. Cannabidiol should be discontinued in patients with elevations of transaminase levels greater than 3 times the ULN and bilirubin levels greater than 2 times the ULN. Patients with sustained transaminase elevations of greater than 5 times the ULN should also have treatment discontinued. Patients with prolonged elevations of serum transaminases should be evaluated for other possible causes. Also consider dosage adjustment or discontinuation of any coadministered medication that is known to affect the liver.', 'Synergism', 'Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360484, 'Carbamazepine', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360485, 'Cenobamate', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360486, 'Ceritinib', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360487, 'Chloramphenicol', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360488, 'Cimetidine', 'Axitinib', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360489, 'Ciprofloxacin', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360490, 'Clarithromycin', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360491, 'Clofarabine', 'Axitinib', 'Moderate', 'The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.', 'DDInter', 1767317475, 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360492, 'Clotrimazole', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360493, 'Cobicistat', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360494, 'Conivaptan', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360495, 'Crizotinib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360496, 'Cyclosporine', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360497, 'Dabrafenib', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360498, 'Danazol', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360499, 'Darunavir', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360500, 'Dasatinib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360501, 'Deferasirox', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360502, 'Delavirdine', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360503, 'Dexamethasone', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360504, 'Dexlansoprazole', 'Axitinib', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360505, 'Diltiazem', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360506, 'Dronedarone', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360507, 'Duvelisib', 'Axitinib', 'Moderate', 'Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 1767317475, 'Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids).', 'Metabolism', 'Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360508, 'Echinacea', 'Axitinib', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', 'DDInter', 1767317475, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360509, 'Efavirenz', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360510, 'Elagolix', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360511, 'Entrectinib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360512, 'Enzalutamide', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360513, 'Epirubicin', 'Axitinib', 'Moderate', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.', 'DDInter', 1767317475, 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', 'Synergism', 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360514, 'Erythromycin', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360515, 'Eslicarbazepine', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360516, 'Esomeprazole', 'Axitinib', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360517, 'Etravirine', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360518, 'Fedratinib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360519, 'Felbamate', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360520, 'Fluconazole', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360521, 'Goldenseal', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360522, 'Grepafloxacin', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360523, 'Griseofulvin', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360524, 'Idelalisib', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360525, 'Imatinib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360526, 'Indinavir', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360527, 'Interferon beta-1a', 'Axitinib', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 1767317475, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360528, 'Interferon beta-1b', 'Axitinib', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 1767317475, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360529, 'Isavuconazonium', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360530, 'Isoniazid', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360531, 'Itraconazole', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360532, 'Ivacaftor', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360533, 'Axitinib', 'Ivosidenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360534, 'Axitinib', 'Ketoconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360535, 'Axitinib', 'Lansoprazole', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360536, 'Axitinib', 'Lapatinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360537, 'Axitinib', 'Larotrectinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360538, 'Axitinib', 'Lefamulin', 'Moderate', 'When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.', 'DDInter', 1767317475, 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360539, 'Axitinib', 'Leflunomide', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', 'DDInter', 1767317475, 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360540, 'Axitinib', 'Lemborexant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360541, 'Axitinib', 'Lesinurad', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360542, 'Axitinib', 'Letermovir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360543, 'Axitinib', 'Levamlodipine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360544, 'Axitinib', 'Lomitapide', 'Major', 'Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.', 'DDInter', 1767317475, 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360545, 'Axitinib', 'Lonafarnib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360546, 'Axitinib', 'Lorlatinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360547, 'Axitinib', 'Magaldrate', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360548, 'Axitinib', 'Magnesium carbonate', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360549, 'Axitinib', 'Magnesium hydroxide', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360550, 'Axitinib', 'Magnesium oxide', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360551, 'Axitinib', 'Methylphenobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360552, 'Axitinib', 'Methotrexate', 'Moderate', 'Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.', 'DDInter', 1767317475, 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360553, 'Axitinib', 'Miconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360554, 'Axitinib', 'Mifepristone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360555, 'Axitinib', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', 'DDInter', 1767317475, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360556, 'Axitinib', 'Mitotane', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360557, 'Axitinib', 'Modafinil', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360558, 'Axitinib', 'Nafcillin', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360559, 'Axitinib', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', 'DDInter', 1767317475, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360560, 'Axitinib', 'Nefazodone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360561, 'Axitinib', 'Nelfinavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360562, 'Axitinib', 'Nevirapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360563, 'Axitinib', 'Nilotinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360564, 'Axitinib', 'Nizatidine', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360565, 'Axitinib', 'Omeprazole', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360566, 'Axitinib', 'Osilodrostat', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360567, 'Axitinib', 'Oxcarbazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360568, 'Axitinib', 'Pantoprazole', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360569, 'Axitinib', 'Pazopanib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360570, 'Axitinib', 'Pegaspargase', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 1767317475, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360571, 'Axitinib', 'Peginterferon beta-1a', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', 'DDInter', 1767317475, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360572, 'Axitinib', 'Pentobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360573, 'Axitinib', 'Pexidartinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360574, 'Axitinib', 'Phenobarbital', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360575, 'Axitinib', 'Phenylbutazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360576, 'Axitinib', 'Phenytoin', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360577, 'Posaconazole', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360578, 'Primidone', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360579, 'Ranitidine (bismuth citrate)', 'Axitinib', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360580, 'Ranolazine', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360581, 'Remdesivir', 'Axitinib', 'Moderate', 'Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.', 'DDInter', 1767317475, 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.', 'Synergism', 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360582, 'Ribociclib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360583, 'Rifabutin', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360584, 'Rifampicin', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360585, 'Rifapentine', 'Axitinib', 'Major', 'Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St. John''s wort should generally be avoided. Although pharmacokinetic data are lacking, the manufacturer recommends that moderate CYP450 3A4 inducers should also be avoided if possible, including but not limited to, bosentan, dabrafenib, dexamethasone, efavirenz, etravirine, modafinil, and nafcillin.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, lumacaftor, mitotane, phenobarbital, phenytoin, rifamycins, and St.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360586, 'Ritonavir', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360587, 'Romosozumab', 'Axitinib', 'Moderate', 'Coadministration of romosozumab with bisphosphonates, denosumab, angiogenesis inhibitors, or corticosteroids may increase the risk of developing osteonecrosis of the jaw (ONJ). The condition can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. Other risk factors for ONJ include cancer, chemotherapy, radiotherapy to the head and neck, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy.', 'DDInter', 1767317475, 'Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw. A routine oral examination should be performed by the prescriber prior to initiation of romosozumab treatment. For patients requiring invasive dental procedures, clinical judgment and risk-benefit assessment should guide the management plan of each patient based on their clinical circumstances. Patients should be advised to seek medical attention if they experience signs and symptoms of ONJ, such as: pain in the mouth, teeth, or jaw; swelling or sores inside the mouth; numbness or a feeling of heaviness in the jaw; loosening of a tooth; or exposure of bone in the jaw.', 'Synergism', 'Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360588, 'Rucaparib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360589, 'Rufinamide', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360590, 'Saquinavir', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360591, 'Secobarbital', 'Axitinib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of axitinib should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360592, 'Selpercatinib', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317475, 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1360593, 'Sodium bicarbonate', 'Axitinib', 'Minor', 'Since the aqueous solubility of axitinib is pH-dependent, with higher pH resulting in lower solubility, drugs that increase the pH of the upper gastrointestinal tract may reduce the oral bioavailability of axitinib. The interaction has been studied with rabeprazole. No dosage adjustment for axitinib is recommended during coadministration with proton pump inhibitors, H2-receptor antagonists, or antacids.', 'DDInter', 1767317475, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
